Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Myovant sciences - The Real Truth

Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Accepts Myovant Sciences and Pfizer's Filing For Review In Uterine Fibroids

Myovant Sciences (NASDAQ: MYOV) and Pfizer (NASDAQ: PFE) received U.S.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Myovant Sciences: Q4 Earnings Insights

Myovant Sciences (NYSE:MYOV) reported its Q4 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Preview: Myovant Sciences

Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Myovant Sciences will report an earnings per share (EPS) of $-0.57.

inkl

Read news from The Economist, FT, and more,
with one subscription

U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months

U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months

The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc.

Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe

Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE:MYOV) Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer. This approval was supported by data from the Phase 3 HERO study. In the HERO study, Orgovyx met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…

SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12

SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12

SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00. Shares of Myovant Sciences are trading up 8.08% over the last 24 hours, at $11.23 per share.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Myovant Sciences's Return on Invested Capital Insights

Myovant Sciences's Return on Invested Capital Insights

Myovant Sciences (NYSE:MYOV) brought in sales totaling $54.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 193.85%, resulting in a loss of $63.45 million.

Myovant Sciences: Q3 Earnings Insights

Myovant Sciences: Q3 Earnings Insights

Myovant Sciences (NYSE:MYOV) reported its Q3 earnings results on Wednesday, January 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

1

Organisations

Palantir Technologies

B of A Securities

Bed, Bath & Beyond

Charter Communications

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Prostate Cancer

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play